S&P 500   4,133.04 (-0.74%)
DOW   34,055.88 (-0.30%)
QQQ   306.50 (-1.09%)
AAPL   152.96 (-1.09%)
MSFT   272.28 (+1.76%)
META   185.46 (-3.21%)
GOOGL   99.66 (-7.41%)
AMZN   100.30 (-1.77%)
TSLA   201.97 (+2.62%)
NVDA   224.14 (+1.09%)
NIO   10.70 (-2.01%)
BABA   104.66 (-0.80%)
AMD   86.23 (+0.37%)
T   19.20 (-0.26%)
F   13.55 (+0.74%)
MU   61.56 (-0.92%)
CGC   2.80 (-0.71%)
GE   81.68 (-0.52%)
DIS   111.14 (-0.44%)
AMC   5.87 (-5.02%)
PFE   43.86 (+0.62%)
PYPL   81.25 (-2.38%)
NFLX   362.82 (-0.04%)
S&P 500   4,133.04 (-0.74%)
DOW   34,055.88 (-0.30%)
QQQ   306.50 (-1.09%)
AAPL   152.96 (-1.09%)
MSFT   272.28 (+1.76%)
META   185.46 (-3.21%)
GOOGL   99.66 (-7.41%)
AMZN   100.30 (-1.77%)
TSLA   201.97 (+2.62%)
NVDA   224.14 (+1.09%)
NIO   10.70 (-2.01%)
BABA   104.66 (-0.80%)
AMD   86.23 (+0.37%)
T   19.20 (-0.26%)
F   13.55 (+0.74%)
MU   61.56 (-0.92%)
CGC   2.80 (-0.71%)
GE   81.68 (-0.52%)
DIS   111.14 (-0.44%)
AMC   5.87 (-5.02%)
PFE   43.86 (+0.62%)
PYPL   81.25 (-2.38%)
NFLX   362.82 (-0.04%)
S&P 500   4,133.04 (-0.74%)
DOW   34,055.88 (-0.30%)
QQQ   306.50 (-1.09%)
AAPL   152.96 (-1.09%)
MSFT   272.28 (+1.76%)
META   185.46 (-3.21%)
GOOGL   99.66 (-7.41%)
AMZN   100.30 (-1.77%)
TSLA   201.97 (+2.62%)
NVDA   224.14 (+1.09%)
NIO   10.70 (-2.01%)
BABA   104.66 (-0.80%)
AMD   86.23 (+0.37%)
T   19.20 (-0.26%)
F   13.55 (+0.74%)
MU   61.56 (-0.92%)
CGC   2.80 (-0.71%)
GE   81.68 (-0.52%)
DIS   111.14 (-0.44%)
AMC   5.87 (-5.02%)
PFE   43.86 (+0.62%)
PYPL   81.25 (-2.38%)
NFLX   362.82 (-0.04%)
S&P 500   4,133.04 (-0.74%)
DOW   34,055.88 (-0.30%)
QQQ   306.50 (-1.09%)
AAPL   152.96 (-1.09%)
MSFT   272.28 (+1.76%)
META   185.46 (-3.21%)
GOOGL   99.66 (-7.41%)
AMZN   100.30 (-1.77%)
TSLA   201.97 (+2.62%)
NVDA   224.14 (+1.09%)
NIO   10.70 (-2.01%)
BABA   104.66 (-0.80%)
AMD   86.23 (+0.37%)
T   19.20 (-0.26%)
F   13.55 (+0.74%)
MU   61.56 (-0.92%)
CGC   2.80 (-0.71%)
GE   81.68 (-0.52%)
DIS   111.14 (-0.44%)
AMC   5.87 (-5.02%)
PFE   43.86 (+0.62%)
PYPL   81.25 (-2.38%)
NFLX   362.82 (-0.04%)
OTCMKTS:MRMD

MariMed - MRMD Stock Forecast, Price & News

$0.42
0.00 (0.00%)
(As of 02/7/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.40
$0.44
50-Day Range
$0.36
$0.55
52-Week Range
$0.28
$0.89
Volume
341,141 shs
Average Volume
264,012 shs
Market Capitalization
$142.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$0.85

MariMed MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
102.4% Upside
$0.85 Price Target
Short Interest
Healthy
0.00% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
-33.33%
From $0.03 to $0.02 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

MRMD stock logo

About MariMed (OTCMKTS:MRMD) Stock

MariMed, Inc. engages in direct owning of cannabis licenses and management of seed-to-sale operations. It focuses on the development, operation, management, and optimization of facilities for the cultivation, production, and dispensing of medicinal and recreational cannabis and cannabis-infused products. The company was founded by Robert N. Fireman and Jon Levine on January 25, 2011 and is headquartered in Norwood, MA.

Receive MRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MariMed and its competitors with MarketBeat's FREE daily newsletter.

MRMD Stock News Headlines

MariMed Announces Fourth Quarter 2022 Earnings Date
Huge Upside Potential With "Staggering" Solar Demand
Global solar demand is "staggering" right now, according to Bloomberg. Solar installations are set to grow 30% this year alone. And the boom is just beginning, with increasing adoption of solar by commercial, non-profit, and public entities. With only 1% of commercial electricity demand served by on-site solar globally, there is HUGE opportunity for growth.
MariMed searches for new CEO after death of Robert Fireman
Huge Upside Potential With "Staggering" Solar Demand
Global solar demand is "staggering" right now, according to Bloomberg. Solar installations are set to grow 30% this year alone. And the boom is just beginning, with increasing adoption of solar by commercial, non-profit, and public entities. With only 1% of commercial electricity demand served by on-site solar globally, there is HUGE opportunity for growth.
MariMed Announces Participation In Upcoming Conferences
MariMed Announces Participation In Upcoming Conferences
MariMed Supports Giving At Thanksgiving
MariMed Reports Third Quarter 2022 Earnings
3 Cannabis Stock Predictions for 2023 - InvestorPlace
MariMed Announces Third Quarter 2022 Earnings Date
MariMed Inc. (MRMD)
Form DEF 14A MARIMED INC. For: Sep 22 - StreetInsider.com
See More Headlines
Receive MRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MariMed and its competitors with MarketBeat's FREE daily newsletter.

MRMD Company Calendar

Last Earnings
11/15/2021
Today
2/08/2023
Next Earnings (Estimated)
3/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:MRMD
Fax
N/A
Employees
260
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$0.85
High Stock Price Forecast
$0.85
Low Stock Price Forecast
$0.85
Forecasted Upside/Downside
+102.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$7.22 million
Pretax Margin
13.56%

Debt

Sales & Book Value

Annual Sales
$121.46 million
Cash Flow
$0.07 per share
Book Value
$0.11 per share

Miscellaneous

Free Float
260,232,000
Market Cap
$142.57 million
Optionable
Not Optionable
Beta
3.06

Key Executives

  • Jon R. Levine
    President, CEO, Secretary, Treasurer & Director
  • Timothy Shaw
    Chief Operating Officer
  • Susan M. Villare
    Chief Financial Officer
  • Jay O’Malley
    Vice President-Marketing & Research & Development
  • Ryan Crandall
    Chief Revenue Officer













MRMD Stock - Frequently Asked Questions

Should I buy or sell MariMed stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MariMed in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MRMD shares.
View MRMD analyst ratings
or view top-rated stocks.

What is MariMed's stock price forecast for 2023?

3 Wall Street analysts have issued 1-year price targets for MariMed's stock. Their MRMD share price forecasts range from $0.85 to $0.85. On average, they predict the company's stock price to reach $0.85 in the next twelve months. This suggests a possible upside of 102.4% from the stock's current price.
View analysts price targets for MRMD
or view top-rated stocks among Wall Street analysts.

How have MRMD shares performed in 2023?

MariMed's stock was trading at $0.3562 at the beginning of the year. Since then, MRMD shares have increased by 17.9% and is now trading at $0.42.
View the best growth stocks for 2023 here
.

When is MariMed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our MRMD earnings forecast
.

How were MariMed's earnings last quarter?

MariMed Inc. (OTCMKTS:MRMD) released its quarterly earnings results on Monday, November, 15th. The company reported $0.01 earnings per share (EPS) for the quarter. The company earned $33.21 million during the quarter. MariMed had a net margin of 1.79% and a trailing twelve-month return on equity of 5.18%.

What guidance has MariMed issued on next quarter's earnings?

MariMed updated its FY 2022 earnings guidance on Monday, November, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $132.00 million-$135.00 million, compared to the consensus revenue estimate of $135.80 million.

What other stocks do shareholders of MariMed own?
What is MariMed's stock symbol?

MariMed trades on the OTCMKTS under the ticker symbol "MRMD."

How do I buy shares of MariMed?

Shares of MRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MariMed's stock price today?

One share of MRMD stock can currently be purchased for approximately $0.42.

How much money does MariMed make?

MariMed (OTCMKTS:MRMD) has a market capitalization of $142.57 million and generates $121.46 million in revenue each year.

How many employees does MariMed have?

The company employs 260 workers across the globe.

How can I contact MariMed?

MariMed's mailing address is 11 ROYAL ROAD, BROOKLINE MA, 02445. The official website for the company is marimedadvisors.com. The company can be reached via phone at (617) 795-5140 or via email at ir@mattio.com.

This page (OTCMKTS:MRMD) was last updated on 2/8/2023 by MarketBeat.com Staff